Given that we specifically examined daily aspirin use for at least 5 years,
we might have expected to observe larger reductions in cancer risk than those reported by the meta-analyses.
Instead,
our results suggest that even long-term daily aspirin use is likely to be associated with relatively small,
although still potentially clinically relevant,
reductions in cancer risk.